John Fanikos Shares Greg Piazza’s Presentation On The Results of The HI-Pro Trial
John Fanikos, Director of Strategic Initiatives at North American Thrombosis Forum, shared on LinkedIn:
”The best part of my pharmacist career was spending time with the Thrombosis Research Group.
Dr. Greg Piazza presented the results of the HI-Pro Trial at the European Society Meeting over the Labor Day weekend in Madrid, Spain.
There are often reasons (surgery, infection, injury) patients developed blood clots (deep vein thrombosis and pulmonary embolism) in their legs and lungs.
These events were called “provoked” and treated with medicines (anticoagulants) for 3-6 months.
Dr. Piazza’s research suggests treating longer, and with a lower dose, may prevent repeat events and be better for patients.
Kudos to the research group. Kudos to the Investigational Drug Service Pharmacy (IDS) that delivered the drugs by foot, by FedEx, and by UPS in the peri-pandemic period to keep patients on their medications.
I was honored to be included.”
Stay updated on the latest news in the field of thrombosis with Hemostasis Today.
-
Sep 9, 2025, 23:00Blood Podcast Alert: LSD1 Inhibitors in SCD, Ruxolitinib+Dex in HLH, Low VWF Insights
-
Sep 9, 2025, 15:47AFib: A Hidden Stroke Risk
-
Sep 9, 2025, 07:56Mortality Risk in Thrombotic Thrombocytopenic Purpura․ Insights from Laboratory Biomarkers
-
Sep 9, 2025, 06:21Vincentius Liong on Nanorobot Swarms vs Blood Clots
-
Sep 9, 2025, 05:53Noel Hiney Highlights the Value of Blood Donation and Community Support
-
Sep 10, 2025, 08:20Flora Peyvandi on Caplacizumab: Which VWF Assays Truly Measure Treatment Effectiveness?
-
Sep 10, 2025, 03:36International Journal of Stroke: Rising Incidence of Stroke in Young Adults
-
Sep 9, 2025, 19:11John Fanikos Shares Greg Piazza's Presentation On The Results of The HI-Pro Trial
-
Sep 9, 2025, 08:15Taha Ahmed Highlights Rare Case: LV Fibroelastoma Mimicking Thrombus Leading to Takotsubo
-
Sep 9, 2025, 08:14JAMA Neurology: MRI Aneurysm Wall Enhancement Predicts Risk of Intracranial Aneurysm Growth or Rupture
-
Sep 9, 2025, 20:15Linking a Single Dominant Antibody to HIT: A Novel Study Led by Ishac Nazy, Donald Arnold, and John G. Kelton
-
Sep 8, 2025, 14:24Von Willebrand Factor as a Therapeutic Target․ From Development to Clinical Application
-
Sep 8, 2025, 02:35Reza Shojaei on the Real Worth of Hemoglobin Oxygen Carriers – HBOCs
-
Sep 7, 2025, 14:16Mary Kiige: Biological Hemoglobin Oxygen Carrier as a Lifesaving Oxygen Bridge
-
Sep 7, 2025, 14:13Breakthrough in Blood: Cécile Denis and INSERM Team Develop Nanobody Therapy for Type 1 VWD
-
Sep 9, 2025, 10:34James Douketis Receives the 2025 Distinguished Service Award in General Internal Medicine!
-
Sep 9, 2025, 08:07Hemophilia Federation of America Launches ‘Blood Brothers’ Podcast for Men With Bleeding Disorders
-
Sep 9, 2025, 04:57World Thrombosis Day 2025: Louise Bannon Invites Donations and Partnerships
-
Sep 8, 2025, 15:10Michael Makris on WHO’s Essential Medicines List Update: A Win for the Global Haemophilia Community
-
Sep 8, 2025, 14:26European Haemophilia Consortium Marks World PT Day: Physiotherapy Empowers People with Bleeding Disorders